Publications, posters & presentations

Publications, posters & presentations -
our significant research

Filter
Research Area
Technology
Resource type
Category
123 results found
Nov 22, 2023
Publication
Novavax led
The Journal of Infectious Diseases
COVID-19, Matrix-M™ adjuvant
The Novavax Heterologous COVID Booster Demonstrates Lower Reactogenicity Than mRNA: A Targeted Review
Nov 16, 2023
Publication
Novavax led
The Journal of Infectious Diseases
COVID-19, Matrix-M™ adjuvant
Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-cov-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial
Nov 7, 2023
Publication
Novavax led
Frontiers in Drug Delivery
COVID-19, Matrix-M™ adjuvant
Biodistribution of the Saponin-Based Adjuvant Matrix-M™ Following Intramuscular Injection in Mice
Nov 6, 2023
Publication
Novavax led
Scientific Reports
COVID-19, Matrix-M™ adjuvant
XBB.1.5 spike protein COVID‑19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants
Sep 20, 2023
Publication
Novavax led
Vaccine
COVID-19
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses
Bethanie Wilkinson, Kinjal S. Patel, Katherine Smith, et al.
Sep 20, 2023
Publication
Novavax included/third party
eBioMedicine
COVID-19, Matrix-M™ adjuvant
Risk of COVID-19 after natural infection or vaccination
Anne-Marie Rick, Matthew B. Laurens, Ying Huang, et al.
Aug 31, 2023
Publication
Novavax led
Preprint
COVID-19, Matrix-M™ adjuvant
XBB.1.5 Spike Protein COVID-19 Vaccine Induces Broadly Neutralizing and Cellular Immune Responses Against EG.5.1 and Emerging XBB Variants
Aug 30, 2023
Publication
Collaborative
Vaccine
COVID-19, Matrix-M™ adjuvant
Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults
Jun 16, 2023
Publication
Novavax included/third party
Journal of Infection
COVID-19, Matrix-M™ adjuvant
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial
Angela M. Minassian, Eimear Kelly, et al.
May 21, 2023
Publication
Novavax led
The Journal of Infectious Diseases
COVID-19, Matrix-M™ adjuvant
Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 SARS-CoV-2 Primary Vaccination
Louis Fries, Neil Formica, Raburn M Mallory, et al.